BioCentury | Apr 2, 2001
Finance

Ebb & Flow

...as senior health care equity research analysts. For the last five years, Rauch was at Everen/First...
BioCentury | Jan 10, 2000
Finance

Bigger launching pad

...Dan Durkin will pick up his sellside duties, along with new hire Jeffrey Kraws from Everen...
BioCentury | Oct 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his long-term...
BioCentury | Oct 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his intermediate-term rating...
BioCentury | Jul 19, 1999
Analyst Picks & Changes

Analyst picks & changes

...Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. Business: Drug discovery Everen Securities analyst Albert Rauch began...
BioCentury | Jul 12, 1999
Analyst Picks & Changes

Analyst picks & changes

...Affymetrix Inc. (AFFX), Santa Clara, Calif. Business: Enabling technology Everen Securities analyst Albert Rauch increased his...
BioCentury | Feb 1, 1999
Analyst Picks & Changes

Analyst picks & changes

...Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Business: Cancer, Infectious diseases Everen Securities analyst Albert Rauch raised...
BioCentury | Feb 1, 1999
Analyst Picks & Changes

Analyst picks & changes

...2000 estimate to $4 from $3.86. His new price target is $136, up from $125. Everen...
BioCentury | Jan 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch began coverage with an...
BioCentury | Nov 2, 1998
Analyst Picks & Changes

Analyst picks & changes

...EPS estimate to $3.18 from $3.14 to reflect better than expected third quarter earnings (B13). Everen...
Items per page:
1 - 10 of 23
BioCentury | Apr 2, 2001
Finance

Ebb & Flow

...as senior health care equity research analysts. For the last five years, Rauch was at Everen/First...
BioCentury | Jan 10, 2000
Finance

Bigger launching pad

...Dan Durkin will pick up his sellside duties, along with new hire Jeffrey Kraws from Everen...
BioCentury | Oct 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Amgen Inc. (AMGN), Thousand Oaks, Calif. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his long-term...
BioCentury | Oct 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch lowered his intermediate-term rating...
BioCentury | Jul 19, 1999
Analyst Picks & Changes

Analyst picks & changes

...Incyte Pharmaceuticals Inc. (INCY), Palo Alto, Calif. Business: Drug discovery Everen Securities analyst Albert Rauch began...
BioCentury | Jul 12, 1999
Analyst Picks & Changes

Analyst picks & changes

...Affymetrix Inc. (AFFX), Santa Clara, Calif. Business: Enabling technology Everen Securities analyst Albert Rauch increased his...
BioCentury | Feb 1, 1999
Analyst Picks & Changes

Analyst picks & changes

...Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Business: Cancer, Infectious diseases Everen Securities analyst Albert Rauch raised...
BioCentury | Feb 1, 1999
Analyst Picks & Changes

Analyst picks & changes

...2000 estimate to $4 from $3.86. His new price target is $136, up from $125. Everen...
BioCentury | Jan 4, 1999
Analyst Picks & Changes

Analyst picks & changes

...Biogen Inc. (BGEN), Cambridge, Mass. Business: Biopharmaceuticals Everen Securities analyst Albert Rauch began coverage with an...
BioCentury | Nov 2, 1998
Analyst Picks & Changes

Analyst picks & changes

...EPS estimate to $3.18 from $3.14 to reflect better than expected third quarter earnings (B13). Everen...
Items per page:
1 - 10 of 23